On Tuesday, Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) opened higher 13.41% from the last session, before settling in for the closing price of $0.60. Price fluctuations for ADAP have ranged from $0.42 to $2.05 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 134.88%. Company’s average yearly earnings per share was noted 70.37% at the time writing. With a float of $226.31 million, this company’s outstanding shares have now reached $227.17 million.
Considering the fact that the conglomerate employs 449 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 95.26%, operating margin of -28.14%, and the pretax margin is -28.42%.
Adaptimmune Therapeutics Plc ADR (ADAP) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Adaptimmune Therapeutics Plc ADR is 11.49%, while institutional ownership is 47.97%. The most recent insider transaction that took place on Jun 18 ’24, was worth 22,814. In this transaction Chief Commercial Officer of this company sold 24,531 shares at a rate of $0.93, taking the stock ownership to the 38,293 shares. Before that another transaction happened on Jan 17 ’24, when Company’s Chief Executive Officer sold 30,080 for $0.67, making the entire transaction worth $20,244. This insider now owns 44,848 shares in total.
Adaptimmune Therapeutics Plc ADR (ADAP) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 70.37% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 1.00% during the next five years compared to 10.30% growth over the previous five years of trading.
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Trading Performance Indicators
Check out the current performance indicators for Adaptimmune Therapeutics Plc ADR (ADAP). In the past quarter, the stock posted a quick ratio of 3.82. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.98.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.21, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach -0.09 in one year’s time.
Technical Analysis of Adaptimmune Therapeutics Plc ADR (ADAP)
Compared to the last year’s volume of 1.72 million, its volume of 5.7 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 15.76%. Additionally, its Average True Range was 0.07.
During the past 100 days, Adaptimmune Therapeutics Plc ADR’s (ADAP) raw stochastic average was set at 11.42%, which indicates a significant decrease from 35.92% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 138.51% in the past 14 days, which was higher than the 86.65% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.8602, while its 200-day Moving Average is $1.1214. Nevertheless, the first resistance level for the watch stands at $0.7141 in the near term. At $0.7535, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.8250. If the price goes on to break the first support level at $0.6032, it is likely to go to the next support level at $0.5317. Should the price break the second support level, the third support level stands at $0.4923.
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Key Stats
There are currently 255,883K shares outstanding in the company with a market cap of 172.55 million. Presently, the company’s annual sales total 60,280 K according to its annual income of -113,870 K. Last quarter, the company’s sales amounted to 40,900 K and its income totaled -17,620 K.
